Home » Stocks » HZNP

Horizon Therapeutics PLC (HZNP)

Stock Price: $90.59 USD -4.90 (-5.13%)
Updated Feb 25, 2021 3:59 PM EST - Market closed
After-hours: $89.00 -1.59 (-1.75%) Feb 25, 7:56 PM
Market Cap 21.07B
Revenue (ttm) 2.20B
Net Income (ttm) 389.80M
Shares Out 203.97M
EPS (ttm) 3.61
PE Ratio 25.08
Forward PE 19.80
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $90.59
Previous Close $95.48
Change ($) -4.90
Change (%) -5.13%
Day's Open 94.59
Day's Range 89.77 - 94.99
Day's Volume 3,547,610
52-Week Range 23.81 - 96.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 9 hours ago

Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

The Motley Fool - 1 day ago

The biopharmaceutical company released its latest quarterly update.

Zacks Investment Research - 1 day ago

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

Benzinga - 1 day ago

Shares of Horizon Therapeutics (NASDAQ:HZNP) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 128.57% over the past year to $1.28, which bea...

Business Wire - 1 day ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance

Business Wire - 3 days ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.

GuruFocus - 6 days ago

Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Ba...

Other stocks mentioned: ALXN, GOLD, RP, THRY
Zacks Investment Research - 1 week ago

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 weeks ago

NEW YORK--(BUSINESS WIRE)--Horizon Therapeutics expands partnership with Medidata to speed clinical trial start-up and completion, using a broad range of technology solutions.

Business Wire - 3 weeks ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2020 financial results will be released on Wednesday, Feb. 24, 2021. Foll...

Zacks Investment Research - 3 weeks ago

Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

Other stocks mentioned: VIE
Investors Business Daily - 3 weeks ago

Horizon Pharma saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96. The post Horizon Pharma Sees Rising Composite Rating To 96 appeared first on Investor's Busines...

Benzinga - 3 weeks ago

Horizon Therapeutics PLC (NASDAQ: HZNP), a rare and rheumatic diseases drug company, announced a multibillion-dollar deal Monday to snap up Viela Bio Inc (NASDAQ: VIE). What Happened: Horizon ...

Market Watch - 3 weeks ago

Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the...

Other stocks mentioned: VIE
Business Wire - 3 weeks ago

DUBLIN & GAITHERSBURG, Md.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement un...

Other stocks mentioned: VIE
InvestorPlace - 1 month ago

Growth stocks are a great way to make money. Here are seven of the stronger names in the S&P 500's hottest sectors for investors to consider.

Other stocks mentioned: CHGG, ETSY, HUN, PTON, SQ, TDOC
Investopedia - 1 month ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: BIIB, BIO, CVS, MRNA, PODD, QDEL, TDOC
Zacks Investment Research - 1 month ago

Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

Business Wire - 1 month ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid the most challenging envi...

Seeking Alpha - 1 month ago

Horizon Therapeutics has morphed into a biotech star due to its new compound Tepezza. Tepezza is approved for the treatment of thyroid eye disease otherwise known as TED.

Investopedia - 2 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, BIO, CVS, MRNA, PODD, QDEL, XLRN, XLV
Business Wire - 2 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, ...

Business Wire - 2 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandat...

GuruFocus - 2 months ago

Horizon Therapeutics PLC (NASDAQ:HZNP) and Gilead Sciences Inc (NASDAQ:GILD) are two contrasting stocks from the drug manufacturing industry, in my opinion. What they share is a price that has...

Other stocks mentioned: GILD
Investopedia - 2 months ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMPH, AMRX, BIIB, PAHC, SUPN
Business Wire - 2 months ago

LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon ...

Zacks Investment Research - 2 months ago

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named to Great Place to Work's 2020 Best Workplaces for Parents list, which highlights compani...

Business Wire - 2 months ago

LAKE FOREST, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has provided $1.2 million in additional funding to U.S and international organizations to su...

Zacks Investment Research - 2 months ago

Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in December: 2020 Evercore ISI HealthCONx Confer...

Business Wire - 3 months ago

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gi...

Other stocks mentioned: HALO
Zacks Investment Research - 3 months ago

Let's see if Horizon Therapeutics (HZNP) stock is a good choice for value-oriented investors right now from multiple angles.

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) has been named to the National Association for Business Resources' 2020 list of Best and Brightest Companies to Work For in the...

24/7 Wall Street - 3 months ago

Most experienced investors are well aware of the major indexes that compose the equity markets.

Other stocks mentioned: DKNG, NET, PPD, CDAY
Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Tim Walbert, chairman, president and chief executive officer, has been honored with the 2020 RARE Champion...

Investors Business Daily - 3 months ago

Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans

Horizon Therapeutics on Monday reported a solid quarter with big beats on the top and bottom lines and raised its guidance, thanks in large part to its thyroid eye disease drug Tepezza, which ...

Zacks Investment Research - 3 months ago

Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitant...

Seeking Alpha - 3 months ago

Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q3 2020 Results - Earnings Call Transcript

Investors Business Daily - 3 months ago

Horizon Therapeutics posted third-quarter earnings and sales that easily topped Wall Street expectations and the maker of drugs to treat rare diseases hiked its outlook, but HZNP stock fell. T...

Zacks Investment Research - 3 months ago

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 74.00% and 13.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results and Increases Full-Year Net Sales and Adjusted EBITDA Guidance

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and...

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune's Top Workplaces 2020, ranking number two out of other midsiz...

PRNewsWire - 3 months ago

SEATTLE, Oct. 29, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon...

Business Wire - 3 months ago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in the Infusion Duration Study to Assess Tolerability of Pegloticase A...

Zacks Investment Research - 3 months ago

Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.

Insider Monkey - 3 months ago

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel ...

Zacks Investment Research - 3 months ago

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About HZNP

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disor... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Jul 28, 2011
CEO
Timothy P. Walbert
Employees
1,275
Stock Exchange
NASDAQ
Ticker Symbol
HZNP
Full Company Profile

Financial Performance

In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 110.33, which is an increase of 21.80% from the latest price.

Price Target
$110.33
(21.80% upside)
Analyst Consensus: Buy